Subscribe to our Rss Feed

Control your Diabetes – Care for your Heart!



Filed under : What's UP

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, brought together top endocrinologists, experts in internal medicine and primary care physicians under the theme ‘Control your Diabetes – Care for your Heart’ The event aimed to highlight new solutions in Type 2 diabetes management when it comes to Cardiovascular disease, the primary cause of death in Type 2 diabetes and which cause up to 46 percent of deaths in Egypt.

 

Diabetes affects more than 415 million people worldwide. By 2040, the number of people with diabetes is expected to increase and reach 642 million (the equivalent of one adult in 10). Type 2 diabetes is the most common form of diabetes, responsible for at least 85–95 percent of all diabetes cases. It has been estimated that every six seconds a person dies of diabetes, which translates to over five million deaths a year worldwide. Life expectancy of people with T2D at high CV risk is, on average, decreased by up to twelve years with approximately 50 percent of deaths in people with T2D caused by CV disease.

 

A new drug to manage risk factors associated with Type 2 Diabetes Empagliflozin was launched at the event. Empagliflozin is the only oral medicine approved for Type 2 diabetes management with additional benefit to prevent cardiovascular death in adults with Type 2 diabetes.

 

Mohamed El Dababy, Boehringer Ingelheim’s Head of Human Pharma and General Manager Near East Middle East and Africa (NEMEA) said, “With an increasing section of the population diagnosed with diabetes, the need for ongoing clinical research has never been more important. In Boehringer Ingelhiem, Our focus is to provide innovative approach to managing T2D, and we are building upon our commitment to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, our efforts reflect a growing range of product portfolios and a continued determination to provide sustainable solutions. We will keep on working to ensure innovative treatment options and approaches are available to help more patients.  We are also committed to serving the medical community, with studies and product information to help address the needs of those living with diabetes.”

 

New approaches to reduce blood sugar levels were amongst topics discussed by the experts during the panel discussion.  Blood sugar, if uncontrolled affects the body’s circulatory system, leading to complications such as coronary artery disease, peripheral arterial disease, and stroke in the case of large blood vessels and diabetic nephropathy, neuropathy, and retinopathy when smaller vessels are damaged.

 

 

Prof. Dr. Hesham El Hefnawy, Dean of Egypt National Institute for Diabetes & Endocrinology noted: “Diabetes is on the rise in Egypt, representing a major threat to people’s lifestyles and overall health conditions. At the same time, cardiovascular incidences have also increased over the last few decades in Egyptians due to the high prevalence of major lifestyle risk factors including stress, smoking and poor diet[8]. Completing the annual cycle of care can help achieve better outcomes for people with diabetes. Regular assessments can prevent complications and other adverse outcomes associated with the disease.”

 

Dr. Professor. Ibrahim Naguib Elebrashy, Professor of Internal Medicine at Cairo University affirmed that: “Despite advances in care, cardiovascular disease is still the number one cause of death among people with type 2 diabetes. Even after receiving standard care treatments, people with type 2 diabetes and established cardiovascular disease are still at risk and need additional cardio-protection. EMPA-REG OUTCOME® trial showed that Empagliflozin significantly reduced the risk of the combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care in adults with Type 2 Diabetes and established cardiovascular disease.”

Leave a reply